Avalyn Pharma Inc.’s (NASDAQ:AVLN) Lock-Up Period To Expire on October 27th

Avalyn Pharma’s (NASDAQ:AVLN) lock-up period will end on Tuesday, October 27th. Avalyn Pharma had issued 16,666,667 shares in its IPO on April 30th. The total size of the offering was $300,000,006 based on an initial share price of $18.00. After the end of the company’s lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on AVLN. Weiss Ratings started coverage on Avalyn Pharma in a research note on Thursday, August 13th. They set a “sell (d+)” rating for the company. Wall Street Zen downgraded Avalyn Pharma from a “hold” rating to a “sell” rating in a research note on Sunday, September 20th. Raymond James Financial began coverage on Avalyn Pharma in a research note on Friday, October 2nd. They issued an “outperform” rating and a $60.00 price objective on the stock. Finally, Morgan Stanley boosted their target price on Avalyn Pharma from $53.00 to $57.00 and gave the stock an “overweight” rating in a report on Thursday, August 13th. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Avalyn Pharma presently has a consensus rating of “Moderate Buy” and an average price target of $60.00.

Avalyn Pharma Price Performance

Shares of Avalyn Pharma stock opened at $25.11 on Thursday. Avalyn Pharma has a 52-week low of $22.24 and a 52-week high of $40.17. The company has a debt-to-equity ratio of 0.04, a quick ratio of 33.12 and a current ratio of 33.12. The firm has a fifty day simple moving average of $31.82.

Avalyn Pharma (NASDAQ:AVLN) last posted its earnings results on Wednesday, August 12th. The company reported ($0.98) EPS for the quarter, topping the consensus estimate of ($1.03) by $0.05. As a group, research analysts anticipate that Avalyn Pharma will post -3.86 EPS for the current year.

Institutional Investors Weigh In On Avalyn Pharma

Institutional investors and hedge funds have recently made changes to their positions in the company. Bank of New York Mellon Corp acquired a new position in Avalyn Pharma in the second quarter valued at approximately $1,321,000. State Street Corp bought a new position in Avalyn Pharma in the second quarter valued at approximately $10,501,000. Braidwell LP acquired a new stake in Avalyn Pharma during the 2nd quarter worth $26,382,000. Finally, Montanova Capital LLC acquired a new stake in Avalyn Pharma during the 2nd quarter worth $82,402,000.

Avalyn Pharma Company Profile

Avalyn Pharma, Inc (NASDAQ: AVLN) is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for patients with pulmonary fibrosis and other serious respiratory diseases. The company’s research is aimed at delivering established antifibrotic medicines directly to the lungs, with the potential to improve treatment effectiveness while reducing systemic exposure and associated side effects.

Avalyn’s lead product candidate is AP01, an inhaled formulation of pirfenidone being developed for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis.